HOME >> MEDICINE >> NEWS
Omega-3 fatty acids may slow cognitive decline in some patients with very mild Alzheimer's disease

Omega-3 fatty acid supplements may slow cognitive decline in some patients with very mild Alzheimer's disease, but do not appear to affect those with more advanced cases, according to results of a clinical trial published in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

Alzheimer's disease is a severely debilitating condition that affects thinking, learning and memory, beginning with declines in episodic memory (including memory about events in one's own life), according to background information in the article. Medications are available to treat the symptoms, but these drugs do not affect the underlying cause and progression of the disease. Several studies have shown that eating fish, which is high in omega-3 fatty acids, may protect against Alzheimer's disease, leading researchers to question whether supplements could have similar effects.

Yvonne Freund-Levi, M.D., Karolinska Institutet, Stockholm, Sweden, and colleagues compared the effects of supplements containing two omega-3 fatty acids with placebo in 204 patients with Alzheimer's disease, 174 of whom completed the entire study. For six months, 89 patients (51 women and 38 men) took 1.7 grams of docosahexaenoic acid (DHA) and .6 grams of eicosapentaenoic acid (EPA), while 85 patients (39 women and 46 men) took placebo. For an additional six months, both groups took the omega-3 fatty acids. Patients had physical examinations, which included blood tests and blood pressure measurement, and took cognitive tests at the beginning of the study and at the six- and 12-month marks.

After six months, there was no difference in the rate of cognitive decline between the two groups. However, among a subgroup of 32 patients with very mild cognitive impairment at the beginning of the study, those who took the fatty acids experienced less decline in six months compared with those who took placebo. Among those who took placebo during the first six months, de
'"/>

Contact: Jan Palmblad
jan.palmblad@ki.se
JAMA and Archives Journals
9-Oct-2006


Page: 1 2

Related medicine news :

1. Omega-3 fatty acids may slow down early Alzheimers in some cases
2. The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient
3. Omega-3 offers hope for new anti-breast cancer drugs
4. Can an omega-3 fatty acid slow the progression of Alzheimers disease?
5. Long-term effects of non-alcoholic fatty liver disease
6. Researchers estimate significant fatty liver disease in children
7. UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
8. Patients with nonalcoholic fatty liver disease have an increased risk of heart disease
9. Omega 3 fatty acids influence mood, impulsivity and personality, study indicates
10. Consumption of omega-3 fatty acids unlikely to significantly reduce risk of cancer
11. Northwestern Memorial researchers aim to find answer to halting the progression of fatty liver

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education for the ... (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart Healthy: ... help nutrition educators and students inform consumers about the health benefits of eating ...
(Date:3/30/2017)... ... March 30, 2017 , ... This ... to President Trump expressing their support for an independent Vaccine Safety Commission. Five ... and one medical journalist, will hold a press conference at 9:00 AM ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ... co-op eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, ... agricultural equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, ...
(Date:3/29/2017)... New York City, NY (PRWEB) , ... March ... ... governing body for men’s and women’s professional squash, announced it has enlisted New ... marketing partner. The agency will develop and procure sponsorship opportunities for the ...
(Date:3/29/2017)... ... ... is the main cause of hay fever in the United States, with an estimated 95 ... May to July each year; with the worst time for sufferers being June and July. ... http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent studies ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... -- The new research portal will provide ... of company reports on UnitedHealth Group , as ... activities in the healthcare industry. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... through a fundamental transformation globally-a shift from a volume-based ...
(Date:3/30/2017)... Mass. , March 30, 2017  Akcea Therapeutics, ... announced the initiation of a Phase 2b dose-ranging study ... established cardiovascular disease. The goal of the study is ... of AKCEA-APO(a)-L Rx in a planned Phase 3 ... is part of Akcea,s strategic collaboration with Novartis to ...
(Date:3/30/2017)... 2017 Research and Markets has announced ... Size & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product ... From 2014 To 2025" report to their offering. ... The ... USD 108.5 billion by 2025. Home-based ...
Breaking Medicine Technology:
Cached News: